{"generic":"Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent","drugs":["Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent"],"mono":{"0":{"id":"jxx6s0","title":"Generic Names","mono":"Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent"},"1":{"id":"jxx6s1","title":"Dosing and Indications","sub":{"0":{"id":"jxx6s1b4","title":"Adult Dosing","mono":"<ul><li>meningococcal group A, C, W-135, and Y conjugate vaccine has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> 0.5 mL IM as a single dose (European Medicines Agency-approved dosing)<\/li><\/ul>"},"1":{"id":"jxx6s1b5","title":"Pediatric Dosing","mono":"<ul><li>meningococcal group A, C, W-135, and Y conjugate vaccine has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>safety and efficacy not established in pediatric patients younger than 12 months<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (12 months or older) 0.5 mL IM as a single dose (European Medicines Agency-approved dosing)<\/li><\/ul>"},"3":{"id":"jxx6s1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Meningococcal infectious disease; Prophylaxis<br\/>"}}},"3":{"id":"jxx6s3","title":"Contraindications\/Warnings","sub":[{"id":"jxx6s3b9","title":"Contraindications","mono":"hypersensitivity to Neisseria meningitidis group A, C, W-135, or Y polysaccharide, tetanus toxoid carrier protein, or any component of the product <br\/>"},{"id":"jxx6s3b10","title":"Precautions","mono":"<ul><li>anaphylaxis may occur following administration<\/li><li>coagulation disorders, including thrombocytopenia; bleeding may occur following IM administration<\/li><li>febrile illness, acute and severe; delay vaccine administration<\/li><li>immunodeficient or receiving immunosuppressive therapy; inadequate immune response to vaccine may occur<\/li><li>meningococcal infection, increased susceptibility due to conditions such as terminal complement deficiencies and anatomic or functional asplenia; inadequate immune response to vaccine may occur<\/li><li>syncope, in some cases with neurological signs, including transient visual disturbance, paraesthesia, and tonic-clonic limb movements, may occur, especially as a psychogenic response to needle injection in adolescents<\/li><li>tetanus vaccine; Nimenrix is not a substitute for the tetanus vaccine<\/li><li>waning of MenA antibodies, rapid, has been reported at 12 months postdose and onward; consider administration of a second dose in patients at risk of exposure to MenA<\/li><\/ul>"},{"id":"jxx6s3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"jxx6s3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"jxx6s4","title":"Drug Interactions","sub":{"1":{"id":"jxx6s4b14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Measles Virus Vaccine, Live (probable)<\/li><\/ul>"},"2":{"id":"jxx6s4b15","title":"Moderate","mono":"<ul>Tetanus Toxoid (established)<\/ul>"}}},"5":{"id":"jxx6s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (14.3% to 33%), Injection site pain (24.1% to 39.9%), Swelling at injection site (11.2% to 17.9%)<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite (10% or greater)<\/li><li><b>Neurologic:<\/b>Headache (10% or greater), Somnolence (10% or greater)<\/li><li><b>Psychiatric:<\/b>Irritability (10% or greater)<\/li><li><b>Other:<\/b>Fatigue (10% or greater), Fever (4% to 17.6%)<\/li><\/ul>"},"6":{"id":"jxx6s6","title":"Drug Name Info","sub":{"2":{"id":"jxx6s6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jxx6s6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"jxx6s9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>IM use only; do not administer intravascularly, intradermally, or subQ<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>refrigerate prefilled syringe or ampule at 2 to 8 degrees C; add entire contents of syringe or ampule to the vial and shake until completely dissolved, resulting in a clear, colorless solution; administer immediately; stable after reconstitution for 24 hours at 30 degrees C<\/li><li>administer IM, preferably into the deltoid muscle, or into the anterolateral thigh in children 12 to 23 months of age<\/li><\/ul><\/li><\/ul>"}}}